GB Sciences Inc (GBLX)

[3DYOGI]

You will see a huge rotation into medical marijuana stocks soon if there is something altered with recreational laws.

Sessions will review and potentially roll back aspects of the Cole memo, a set of guidelines established in 2013 that directs the Department of Justice to focus marijuana enforcement efforts on violent crimes and distribution in states without legalization laws.


There has been a huge over reaction and companies like GB Sciences will benefit Big league if it happens.

Know what you own. Pretty Sad people don't do there DD

Donald Trump Wants To Legalize Marijuana

"Medical should happen and leave it up to the states .State by State issue "I know people who are really sick and the medical marijuana helps them"

Perhaps the single most significant development is the work of Dr. Andrea Small-Howard and her team of scientists to define and articulate the real potential of our research. Working with our intellectual property attorneys at Fenwick&West, the science team has carefully defined at least eight potential patents for cannabis-based compounds to treat illnesses and serious, life-changing medical conditions.

The developments I have just described above comprise the "Life Sciences" opportunity. I am quite confident the Life Sciences has the potential to become a billion dollar in sales company on its own.

Medical Marijuana Production Updates on California, Texas and Pennsylvania Each of these states will generate 20 Million in revenue like the Nevada Facility that is up and running. to name a few should be released soon final discussions in all 3 states have been taken place. After reviewing our portfolio of potential cannabis-based medical formulations, we determined that a few, critical modifications to our facility were necessary to ensure our ability to create pharma-grade cannabis for medicines. This is essential because we must have a supply chain and production facility that are complaint with current Good Manufacturing Practices (cGMP) in a much shorter time frame than originally envisioned. We must have this capability in the near-term to produce cannabis compounds for FDA-registered Pilot Studies and then Clinical Trials.

So, the dual strategy of both creating medicines and producing high-quality consumer products fuels our confidence that consumer products is the second "billion dollar" opportunity.


aAmotion was made to change the name of the Company from Growblox Sciences, Inc. to GB Sciences, Inc. This motion also passed, but its implementation is subject to FINRA and SEC approval.

GB Science will not expend additional capital on Growblox devices.



Anything under .40 is a steal.

$GBLX